Clinical Trial Update: Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT） [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab with neoadjuvant concurrent chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN